What we know is a drop, what we don’t know is an ocean.
Isaac Newton - Astronomer, Scientist, Physicist, Philosopher, Mathematician (1643–1727)

Upcoming events and News

WHO Cell Substrate Documents 1959 to 2012

WHO Cell Substrate Documents 1959 to 2012

 

In collaboration with WHO, IABS has published a collection of eight WHO documents on cell substrates for the production of biological products to serve as an historical reference and to facilitate an understanding of the evolution of issues and positions that have been taken since the 1950s.

The following link will bring you to the distributor and more information on this book.

http://www.lulu.com/content/paperback-book/animal-cell-substrates/21548826

Narcolepsy and Pandemic Influenza Vaccination

SAVE THE DATE

Narcolepsy and Pandemic Influenza Vaccination
What we know and what we need to know before the next Pandemic

 March 26-27, 2018
Eurostation II, Place Victor Horta
Brussels, Belgium

This meeting will be held under Chatham House Rule

Influenza Pandemics occur when an influenza strain circulates that humans have been exposed to before. This may lead to widespread circulation and a high case fatality rate.

In 2009 pandemic, several H1N1 vaccines were developed against the new H1N1 virus and were extensively used. In Finland and Sweden an increase in narcolepsy was noted after the mass vaccination with one of these vaccines.  Disparate results were seen in other countries with other vaccines.  In addition, an increase of narcolepsy has been reported in countries in Asia following wild type influenza infection.

The goal of this meeting is to be prepared for the next pandemic:

  • What are the latest data on the risk of narcolepsy following exposure to 2009 pandemic vaccines?
  • What scientific data are available and what data are lacking to explain the phenomena that was seen in 2009-10?
  • What additional work is needed to prepare for potential use of adjuvanted vaccines for a future pandemic ?  

More information coming soon

4th Cell Therapy Conference

SAVE THE DATE

4th Cell Therapy Conference
Manufacturing and Testing of Pluripotent Stem Cells

   Organized by
The International Alliance for Biological Standardization
IABS
with support from and in collaboration with the
California Institute for Regenerative Medicine
CIRM
Los Angeles, Cal
ifornia
June 5-6, 2018

Objectives and Expected Outcomes

The 2018 Cell Therapy conference will identify key unresolved issues that need to be addressed for the manufacture and testing of cell therapies and provide scientific consensus on selected aspects to inform the drafting of future national and international guidance. The meeting will bring together representatives from industry, academia, health services and regulatory bodies.

The overall goal of the conference is to provide the target audience with an appreciation of the importance of a well-controlled manufacturing process for cell therapies that are in development, and to hi-lite specific areas that should be considered during early product development in order to avoid issues in later stages. The target audience includes those individuals and organizations actively pursuing research and development of cell therapies with the intent of achieving products that meets regulatory requirements for approval, thus becoming generally available to treat patients with unmet medical needs. 

We will build on previous meetings that generally addressed broader themes of cell therapy studies and manufacturing issues. In addition to reviewing information on the state-of-the-art and recently generated data, this conference ill drill down to key practical issues facing cell therapy developers and regulators to expedite the safe and efficient introduction of new treatments for important diseases where unmet medical needs exist.

More specifically, the conference is expected to provide a basis for new and/or additional guidance on regulatory expectations for developing acceptable cell therapy products including testing requirements during manufacture. Concrete conclusions and recommendations will be important outcomes, which are expected to stimulate the field to move forward in a transparent and coordinated manner.

More information coming soon.

 

In Brief

  • A few words from the President

    The IABS has had a busy and productive year and I am pleased to report to you some of our latest events and activities.
    As President, one of my objectives has been to increase outreach and expand the visibility of IABS among other organizations that have missions similar to, or aligned with IABS.
    Read more

  • IABS Communication Committee

    Recognizing the need for improving the communication process, the IABS Board of Directors established a Communication Committee at the June 2016 Board meeting in Lyon, France. 

    Learn more here

  • Vac2Vac

    VAV2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods. The initiative that started on 1 March 2016 aims to provide the data to support the "Consistency Approach" for quality control of established vaccines, where current quality control approaches are often relying on in vivo methods.

    VAC2VAC is a public-private consortium of twenty partners, involving experts from veterinary and human vaccine industry in a partnership with official medicines control laboratories, academia, translational research organisations, and vaccinology alliances. To achieve their goal, the project partners will develop, optimise and evaluate physico-chemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies. The ultimate goal of the project is to develop tests and approaches that will allow acceptance of the "Consistency Approach" for established vaccines by the regulatory agencies and thereby significantly reducing in the future the use of animals for batch testing in routine vaccine production.

    Press release

    Learn More

  • ZAPI

    About ZAPI - The new Zoonoses Anticipation and Preparedness Initiative (ZAPI), part of the Innovative Medicines Initiative (IMI) public-private partnership, aims to enable swift response to major new infectious disease threats in Europe and throughout the world by designing new manufacturing processes (up to large scale) for delivering effective control tools (vaccines, antibodies/antibody-like molecules) against (re-)emerging zoonotic diseases with pandemic potential within a few months after the occurrence of first cases…

    Learn more

  • Harmonized Safety Monitoring of Immunization in Pregnancy

    The important Harmonized Safety Monitoring of Immunization in Pregnancy International Consensus Conference was recently held at the NIH in Bethesda, Maryland and highlighted progress to date in harmonizing safety monitoring of immunization in pregnancy.

    Learn more about the Harmonized Safety Monitoring of Immunization in Pregnancy ICC here

  • Scientific Committees

    IABS scientific activities are the responsibility of the Scientific Conference Committees, representing special interests within the fields of Human Biologicals and Veterinary Biologicals.
    The Scientific Conference Committees are responsible for the organization of scientific conferences.

    Human Vaccine Committee
    Chairpersons:

    Human Cell & Gene Therapy Committee
    Chairperson: Takao Hayakawa (Japan)

    Human Biotherapeutics Committee
    Chairperson: Anthony Mire-Sluis (USA)

    Veterinary Biologicals Committee
    Chairperson: Carmen Jungbäck (Germany)


    Please find all the biosketches in the Documents section

  • MoU

    IABS has signed an MoU with the following organization:

    Fondation Mérieux

  • Emerging infectious diseases of animals

    Slides from Budapest workshop now posted in Past Conferences or folder here

  • Call for Communications Committee

    At the start of this New Year, we would like to solicite your interest in joining the recently established IABS Communications Committee.

    Read more  pdf here (414 KB)

     

  • Emerging Diseases in Animals: Recommendations & Conclusions

    A comprehensive discussion on all aspects of Emerging Diseases in Animals led to some important observations and conclusions.

    Read more pdf here (457 KB)

     

  • 1

Latest news

  • IABS “3R” Conferences Highlighted in Presentation at the 10th World Congress on Alternatives and Animal Use in the Life Sciences.

    August 24, 2017, an overview of IABS’ “3R” Conferences, Symposia and Workshops was included in a presentation at the vaccine session at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle Washington (See Summary Slide below).  The World Congress are periodic scientific meetings with emphasis on the latest technologies for reduction and replacement of animals and innovations in approaches to ethics, animal welfare and public policy.   Interestingly, the World Congress’ first meeting was in 1993, within one year of the IABS’s first Langen Symposium.  The 11th World Congress is scheduled for 2020 in the Netherlands. 

    In general, World Congress participants were aware of IABS’ leadership in the “3R” and Animal “Alternatives” arena and several inquired about the status of future IABS conferences.   The meeting presented an opportunity to discuss IABS overall, but also the organizations strategic priority to host “3R” related meetings by the North American and European Affiliates.

    Respectfully submitted,

    Rick Hill, IABS Communication Committee Chair

     

  • IABS Presentation to the U.S. Veterinary Biologics Training Program

    In May 2017, an overview of IABS’ mission and activities was presented at the U.S. Veterinary Biologics Training Program. The training program is co-sponsored by the USDA APHIS Center for Veterinary Biologics, the USDA APHIS National Veterinary Services Laboratories and the ISU College of Veterinary Medicine’s Institute for International Cooperation in Animal Biologics (IICAB). The IICAB was founded in 1995 by the USDA Animal and Plant Health Inspection Service and Iowa State University. In June 1998, the IICAB received designation as a component of the World Organization for Animal Health (OIE) Collaborating Centre for the Diagnosis of Animal Diseases and Vaccine Evaluation in the Americas. The designation is shared with the USDA APHIS National Veterinary Services Laboratories (NVSL) and Center for Veterinary Biologics (CVB).


    The first Veterinary Biologics Training Program was held in June 1996 at the ISU College of Veterinary Medicine. The training program has been offered each year since then. More than 2500 individuals have attended the program including over 700 international participants from 90 different countries. More than 160 participants attended in 2017. The program is known worldwide as a premier training program in immunology and veterinary vaccines. Many individuals who have participated in the training continue to be actively involved with veterinary biologics issues and activities world-wide.


    Training Program participants were keenly interested in IABS and had many questions. Complimentary IABS Membership for 2017-2018 was offered to participants and more than 40 accepted the offer. IABS is looking forward to some of the new members attending upcoming conferences and workshops and becoming more actively involved with our organization.


    Respectfully submitted,
    Rick Hill, IABS Communication Committee Chair

     

  • 1
  • 2

IABS-EU Heads Work Package in new IMI project: VAC2VAC

VAV2VAC is a wide-ranging collaborative research project funded by IMI2 which aims to develop and validate quality testing approaches for both human and veterinary vaccines using non-animal methods. The initiative that started on 1 March 2016 aims to provide the data to support the "Consistency Approach" for quality control of established vaccines, where current quality control approaches are often relying on in vivo methods.

VAC2VAC is a public-private consortium of twenty partners, involving experts from veterinary and human vaccine industry in a partnership with official medicines control laboratories, academia, translational research organisations, and vaccinology alliances. To achieve their goal, the project partners will develop, optimise and evaluate physico-chemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies. The ultimate goal of the project is to develop tests and approaches that will allow acceptance of the "Consistency Approach" for established vaccines by the regulatory agencies and thereby significantly reducing in the future the use of animals for batch testing in routine vaccine production.

Learn More

Press Release…

ZAPI

About ZAPI - The new Zoonoses Anticipation and Preparedness Initiative (ZAPI), part of the Innovative Medicines Initiative (IMI) public-private partnership, aims to enable swift response to major new infectious disease threats in Europe and throughout the world by designing new manufacturing processes (up to large scale) for delivering effective control tools (vaccines, antibodies/antibody-like molecules) against (re-)emerging zoonotic diseases with pandemic potential within a few months after the occurrence of first cases…

Learn more

 


IABS-EU is officially recognized by French authorities as a nonprofit organization.

You will be hearing more about IABS-EU in the months ahead.

Founding Members :

Read more:

International Alliance for Biological Standardization


Twitter Feed

#IABS #NextGeneration Sequencing for#AdventitiousVirus detection in #biologics October 26-27 https://t.co/Hleep8TKDU
#IABS #NextGenerationSequencing #AdventitiousVirus detection #biologics: Reference tools for #adventitiousvirus detection by #metagenomics
Follow IABS_global on Twitter

Contact Info

IABS, Rue de la Vallée, 3
CH-1204 Geneva

Switzerland
+ 41 22 301 10 36
+ 41 22 301 10 37
This email address is being protected from spambots. You need JavaScript enabled to view it.